A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery
Latest Information Update: 20 Feb 2026
At a glance
- Drugs Ketorolac (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Adverse reactions; First in man
- Sponsors Surge Therapeutics
Most Recent Events
- 17 Feb 2026 Planned End Date changed from 1 Sep 2025 to 10 Apr 2026.
- 17 Feb 2026 Planned primary completion date changed from 1 Sep 2025 to 10 Apr 2026.
- 17 Feb 2026 Status changed from recruiting to active, no longer recruiting.